CIL Reddit Mentions | ChartExchange

**Public-source BCCL / BHARATCOAL investor update**
*Prabhat Khabar*, Dhanbad City, has reported on **3 August 2026** that a Coal India vigilance review identified **614 sensitive-post rotation cases at BCCL**, of which only **86 were completed and 528 remained pending**.
That implies a reported completion rate of only **14.0%**, with **86.0% pending**.
The subsidiary table printed in the report shows:
• BCCL: **528 pending**
• NCL: **93**
• ECL: **91**
• SECL: **87**
• CMPDI: **71**
• MCL: **15**
• CCL: **2**
On the printed figures, BCCL represents about **59.5% of all pending cases across the seven entities**, even though it represents about **27.5% of identified sensitive posts**. Its pending count is approximately **1.47 times the other six entities combined**.
**Why this is relevant to shareholders**
Sensitive posts reportedly cover functions such as finance, procurement, contracts, production, stores, quality control, security and administration. Rotation is intended as a preventive control, not as proof that an incumbent has done anything wrong.
The **Ministry of Coal** has stated that sensitive-post rotation is part of preventive vigilance and that officials should be rotated after the stipulated tenure. It also recorded that BCCL had already implemented an SAP/ERP alert system for sensitive-post tenure.
That creates the central investor question:
**If automated alerts were operational, why were 528 of 614 reported cases still pending, and what escalation or compensating controls applied meanwhile?**
**The operating and financial context makes the report harder to ignore**
BCCL’s FY2025-26 numbers were already under pressure:
• Production fell **12.30%**, from 40.50 MT to **35.52 MT**.
• Offtake fell **13.62%**, from 38.26 MT to **33.05 MT**.
• Revenue from operations fell **14.28%** to **₹13,644.78 crore**.
• EBITDA fell **66.67%** to **₹785.38 crore**.
• PBT fell **91.24%** to **₹149.18 crore**.
• PAT fell **89.66%** to **₹128.28 crore**.
• Profit per tonne fell from ₹446.84 to **₹46.12**.
• Contractual expenditure was **₹4,482.20 crore**, about **32.8% of revenue**.
• Trade receivables were **₹2,863.18 crore** at March 2026.
• Q1 FY2026-27 remained weak: production fell **27.43%**, offtake fell **14.03%**, and the company reported a **₹68.09 crore PAT loss** and a **₹131.91 loss per tonne**.
**These figures do not prove that delayed rotation caused the underperformance.** BCCL has attributed revenue and operating changes to dispatch, pricing, production and cost factors. The report supplies no financial loss, tender value, customer deduction, inventory difference or production disruption linked to the 528 cases.
The investor relevance is instead that, during a period of thin margins and negative cash generation, shareholders may reasonably seek evidence that control mechanisms in financially significant functions are operating as designed.
**Disclosure check**
I did not find a specific NSE/BSE or BCCL investor-relations clarification on this report as of **3 August 2026, 08:09 IST**. Since this is a same-morning report, this should not be interpreted as delayed disclosure.
Useful clarifications would include:
1) Whether the 614/86/528 figures are accurate and their cut-off date.
2) Area/HQ and department-wise distribution.
3) Number of cases exceeding the normal three-year tenure.
4) Reasons and approving authority for exceptions.
5) Completion timetable and interim supervisory controls.
6) Whether any production, procurement, inventory, receivable or financial impact has been identified.
The investor issue is not to assume wrongdoing. It is to ask whether the reported execution gap is administrative backlog or a wider internal-control matter requiring a dated, quantified update.
**Source:** *Prabhat Khabar*, Dhanbad City, 3 August 2026; attached clipping. Supporting context: Ministry of Coal vigilance report, CIL job-rotation policy and BCCL FY2025-26/Q1 FY2026-27 exchange filings.
**Disclaimer:** This is based on the attached newspaper clipping and public filings. I am treating the clipping’s claims only as reported, not as an independent finding. This is not investment advice and is not a buy, sell, hold, short, entry or exit recommendation. Corrections, the missing page 7, the underlying CVO review, or any company/exchange clarification are welcome.